Online Parent Training Platform for complementary treatment of behavioral disorders in Attention Deficit Hyperactivity Disorder

Not Applicable

Not yet recruiting

Conditions: Disturbance of activity and attention, Hyperkinetic conduct disorder, Oppositional defiant disorder
F90.0
F90.1
F91.3

Registration Number: RBR-6cvc85

Lead Sponsor: Faculdade de Medicina da Universidade Federal de Minas Gerais

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Not yet recruiting

Sex: Male

Target Recruitment: Not specified

Inclusion Criteria

Families whose children have Attention Deficit/Hyperactivity Disorder and/or Oppositional Defiant Disorder; children must have externalizing symptoms such as hyperactivity and/or oppositional behavior; children who are between 6 and 12 years old; male gender

Exclusion Criteria

Families whose children have severe psychiatric comorbidities (i.e. psychosis, bipolar affective disorder, severe depression), genetic or neurological; whose intelligence is below the 5th percentile; feminine gender. Families whose primary caregivers have intelligence below the 5th percentile or have been diagnosed with serious psychiatric conditions (i.e. psychoses, bipolar affective disorder, severe depression); and families with severe social adversity in the home context (i.e. domestic violence, physical abuse, extreme poverty, hunger)

Study & Design

Study Type: Intervention

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Change in the symptoms of Attention Deficit/Hyperactivity Disorder and/or Oppositional Defiant Disorder, with a decrease in externalizing symptoms, determined by the MTA-SNAP-IV scale: which assesses symptoms of attention deficit/hyperactivity disorder and Oppositional Defiant Disorder in children and adolescents (Mattos, et al., 2006); and the K-SADS-PL 2013 interview: semi-structured interview that raises important information about the history of psychiatric disorders, at the present time and throughout life and assesses the severity of symptoms (Caye, et al., 2017)<br><br>

Secondary Outcome Measures